SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Tables)
 12 Months Ended
Dec. 31, 2017
SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION [Abstract]  
Schedule of Other Current Liabilities
Current liabilities:
 
   
December 31,
  
   
2016
    
2017
  
             
Director fees
  
$
21
    
$
48
  
Trade payables
    
20
      
61
  
Accrued expenses and other
    
196
      
200
  
                 
   
$
237
    
$
309
Schedule of Financial Income (Expenses), Net
Financial expenses, net
 
   
Year ended
December 31,
  
   
2015
    
2016
    
2017
  
                   
Financial expenses:
                  
Loss from change in fair value of investment in BioCancell and sale of BioCancell shares
  
$
(36
)
  
$
-
    
$
-
  
Other
    
(2
)
    
(15
)
    
(3
)
                         
     
(38
)
    
(15
)
    
(3
)
Financial income:
                        
Income from the sale of Biocancell shares
    
-
      
-
      
35
  
Other
    
9
      
12
      
13
  
     
9
      
12
      
48
  
                         
   
$
(29
)
  
$
(3
)
  
$
45